Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans

Executive Summary

King will not pursue a new merger partner following the collapse of its proposed agreement to be acquired by Mylan

You may also be interested in...



King Gets Inventories Under Control; Next Step Is Boosting Brand Sales

King Pharmaceuticals has dramatically reduced wholesale inventory levels and associated product return rates this year, the company said during its Nov. 9 third quarter earnings call

King Gets Inventories Under Control; Next Step Is Boosting Brand Sales

King Pharmaceuticals has dramatically reduced wholesale inventory levels and associated product return rates this year, the company said during its Nov. 9 third quarter earnings call

Generics Infringe On Branded Stock Growth As Investors Eye Mergers, Part D

Generic drug consolidation and the pending implementation of Medicare Part D in January, with its cost pressures likely to benefit unbranded drugs, appear to be swaying investor confidence in favor of generic drug makers

Related Content

Topics

UsernamePublicRestriction

Register

MT142726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel